Immunexpress Group's Series A Round

Immunexpress Group raised a round of funding on March 05, 2014. Investors include Debiopharm Investment.

Immunexpress is a molecular diagnostic company committed to improving outcomes for patients with, and, at risk of, sepsis. The core competency of Immunexpress is the clinical validation of genomic and…

Articles about Immunexpress Group's Series A Round: